The Silent Burden of De Novo Metastatic Prostate Cancer in the Middle East: A Call for Region-Specific Screening Guidelines

Background: Prostate cancer is a significant global health concern, with rising incidence and disease burden in the Middle East (ME). This review aims to explore the current state of prostate cancer epidemiology in the ME, particularly in low- to middle-income settings, investigating trends in incidence and mortality, assessing challenges related to de novo metastatic prostate cancer, and evaluating the need for region-specific screening guidelines. Methods: We conducted a comprehensive narrative review of epidemiological data on prostate cancer in the ME, examining trends in incidence and mortality, de novo metastatic cases, and current screening practices. Additionally, we assessed the applicability of international guidelines for prostate cancer screening to the ME context. Results: The ME exhibits a rising trend in prostate cancer incidence, with a mortality-to-incidence ratio of 0.3–0.4, compared to 0.1 in the United States, reflecting significant differences in healthcare access and quality that contribute to poorer outcomes. The incidence rates are particularly high in Lebanon, reaching 37.2 per 100,000 in 2012. De novo metastatic prostate cancer is also more prevalent in the ME, often exceeding 20–30%, with a value of 23% reported in Lebanon and reaching 54% in a study including six Middle Eastern countries, compared to 4–14% in the United States. Our review identified a critical need for enhanced screening and early detection efforts tailored to the ME’s unique epidemiological and socio-cultural factors. Conclusions: The substantial burden of de novo metastatic prostate cancer in the ME underscores the need for region-specific screening guidelines. Tailored approaches, including increased awareness, early detection, and resource-stratified strategies, are essential to address the unique epidemiological and socio-cultural factors of the ME and improve patient outcomes.